menu search

BCDA / BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and six months ended June 30, 2022 and provide a corporate update by conference call on Wednesday, August 10, 2022 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Read More
Posted: Aug 4 2022, 14:04
Author Name: GlobeNewsWire
Views: 110223

BCDA News  

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

By GlobeNewsWire
November 1, 2023

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the tr more_horizontal

BioCardia (BCDA) Up on Plans for Second Heart Failure Study

By Zacks Investment Research
October 12, 2023

BioCardia (BCDA) Up on Plans for Second Heart Failure Study

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin more_horizontal

BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study

By Zacks Investment Research
September 6, 2023

BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study

Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the pr more_horizontal

BioCardia shares slide on disappointing interim data from heart therapy trial

By Proactive Investors
September 5, 2023

BioCardia shares slide on disappointing interim data from heart therapy trial

BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of CardiAMP cell t more_horizontal

BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 9, 2023

BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates

BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss more_horizontal

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

By GlobeNewsWire
May 3, 2023

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the tre more_horizontal

BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 29, 2023

BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David Mc more_horizontal

BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 12, 2022

BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman more_horizontal


Search within

Pages Search Results: